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Abstract:
Objectives: To determine the incidence and magnitude of the rapid increase in the serum PSA (riPSA) level after high-intensity focused 
ultrasound (HIFU) therapy for prostate cancer, and its correlation with clinical factors.
Methods: A total of 176 patients with localized prostate cancer underwent HIFU therapy. Serum riPSA was determined on the basis of 
the same criteria as those for “PSA bounce”, ie, an increase of $0.2 ng/ml with a spontaneous return to the prebounce level or lower. 
Patients were stratified according to neoadjuvant PSA level, T stage, risk group, age, Gleason score, pretreatment PSA level, post-
treatment PSA nadir, and number of HIFU sessions.
Results: riPSA was seen in 53% of patients during a median follow-up period of 43 months. A PSA nadir was achieved within 3 
months for 85.1% of the treatments. In all cases, onset of riPSA was seen two days after HIFU therapy, and the median magnitude was 
23.69 ng/ml. A magnitude of .2 ng/ml was seen in 89.4% of cases. Univariate analysis revealed that patients with riPSA were associ-
ated with usage of hormonal therapy and the post-treatment PSA nadir level. Multivariate Cox regression analysis revealed that riPSA 
and the number of HIFU sessions were predictors of biochemical recurrence. A significant statistical association was found between the 
presence of riPSA and the risk of biochemical failure only in the low- and intermediate-risk group.
Conclusion: Patients treated with HIFU who experience post-treatment riPSA may have an increased risk of biochemical recurrence, 
especially in non-high-risk patients.
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Introduction
Prostate cancer is the most common cancer in men, 
and the second leading cause of cancer-related death in 
the western world. The mainstay of treatment remains 
radical surgery or radiation therapy, but several mini-
mally invasive treatments are now being evaluated, 
and may prove to be of equivalent oncological value 
in the long term. Transrectal high-intensity focused 
ultrasound (HIFU) is a new minimally invasive thera-
peutic method that is able to achieve tissue coagula-
tion transdermally and/or transmucosally, destroying 
tissue in various conditions. It has a number of clini-
cal applications, including coagulation of pathology 
in the breast, uterus, kidney, spleen, liver, and bone. 
A rapid increase of the serum PSA level (riPSA) is 
usually recognized during the early phase after HIFU 
therapy. This riPSA can be explained by tissue necro-
sis and organ manipulation resulting from treatment. 
However, no study has analyzed the magnitude, tim-
ing, or clinical significance of the riPSA level after 
HIFU  therapy  for  localized  prostate  cancer.  Also, 
there are currently no definitive criteria for this phe-
nomenon. In the present study, we employed the same 
definitive criteria as those for "PSA bounce", ie, an 
increase in the serum PSA level of $0.2 ng/ml with 
spontaneous return to the prebounce level or lower.
The purpose of the present study was to investi-
gate the timing and magnitude of riPSA, and its pre-
dictive value for biochemical recurrence in patients 
with prostate cancer receiving HIFU therapy.
Materials and Methods
Patient selection
Between June 2004 and November 2009, 176 men 
with clinically localized prostate cancer were treated 
using the Sonablate-500® (Focus Surgery, IN, USA), 
which consists of a power generator, a water-cooling 
system ('Sonachill®’), a treatment probe and a probe-
positioning system. In all patients prostate cancer had 
been diagnosed by at least a six-core prostate biopsy. 
All the patients provided written informed consent 
to the treatment following approval from the local 
institutional review board. Decision criteria for rec-
ommendation of HIFU therapy were: clinical stage 
T1/T2 (1997 TNM classification), normal bone scin-
tigraphy results, normal abdominal CT results, and 
patient background, ie, either unwilling to undergo, 
or unfit for, radical prostatectomy. Any previous cura-
tive treatment for prostate cancer was considered as a 
formal exclusion criterion.
We stratified the patients into three risk categories 
according to the classification of D’Amico et al: low 
risk, clinical stage T1c or T2a, Gleason Score (GS) 
less than 6, and PSA , 10 ng/ml; intermediate risk, 
clinical stage T2b, or PSA 10–20 ng/ml, or GS 7; 
and high risk, clinical stage T2c, or PSA 20 ng/ml or 
more, or GS 8–10.
In  every  case,  prostate  volume  was  evaluated 
using ultrasound. In some cases, the HIFU session 
was combined with neoadjuvant hormonal therapy, 
either when the prostate volume was above 30 ml or 
in cases of lower urinary tract voiding symptoms. For 
postoperative  follow-up,  PSA  monitoring  was  per-
formed routinely at 2 days after treatment, at 1 and 3 
months, and then every 3 months. Biochemical recur-
rence of the disease was defined as a rise in the serum 
PSA level of 2 ng/ml or more above the PSA nadir, 
in accordance with the latest Phoenix criteria. The 
investigated PSA nadir value was used as an indica-
tor for prediction of biochemical failure. In addition, 
we performed sextant prostate biopsies in cases of 
biochemical failure. Also, a follow-up control biopsy 
3–6 months after treatment was recommended for all 
patients. Patients with a rising PSA level but nega-
tive control biopsy underwent bone scintigraphy and 
a computed tomography scan to exclude distant met-
astatic disease. Biochemical recurrence-free survival 
rate was evaluated from the date of the first HIFU 
session to the date of the last follow-up visit, or death, 
in all patients as mentioned above.
Statistical analysis
Statistical analysis was performed using the Graph-
Pad Prism® version 5.0 statistical package for Win-
dows  (GraphPad  Software,  San  Diego,  California 
USA) and PASW software version 17 for Windows 
(SPSS Inc., Chicago, IL, USA). The Fisher’s exact 
test and chi-squared test were used to evaluate cate-
gorical comparisons. Biological relapse-free survival 
was defined as the period from random assignment 
to the date of biological relapse, or censored at last 
follow-up. Survival functions were calculated using 
the  Kaplan-Meier  method.  Survival  distributions 
were compared between the two or three arms using PSA increase after high-intensity focused ultrasound for localized prostate cancer
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a log-rank test. All tests and reported P values were 
2-sided, and significance was defined as P , 0.05.
Results
The  clinical  disease  characteristics  and  dosimetric 
parameters of the 176 patients are shown in Table 1. 
The median follow-up period for the entire group was 
43 (range, 2–70) months. At the time of analysis, 40 
men (22.7%) had biochemical failure, of whom 28 
underwent biopsy and 13 (46.4%) had positive biopsy 
findings. The median PSA level after HIFU was 9.91 
(range, 0–268.9) ng/mL, and the median PSA nadir was 
0.03 (range, 0.03–3.31) ng/mL. Of the 176 patients, 
106 (60.2%) had a PSA follow-up of .2 years.
riPSA  was  detected  in  93  men  (52.8%).  In  all 
patients, riPSA was seen at 2 days after HIFU ther-
apy. The median amplitude of the increase was 23.69 
(range,  0.21–258.73)  ng/mL.  Twenty-four  (25.8%) 
of these 93 patients were found to have biochemical 
failure. The biochemical recurrence-free (BCRF) sur-
vival rate was 29% and 21% for those with and with-
out a riPSA, respectively.
Univariate analysis (Table 1) showed that neoadju-
vant hormonal therapy and the PSA nadir were asso-
ciated with riPSA. A riPSA magnitude of .2 ng/mL 
was detected in 89.4% of the patients.
Biochemical  recurrence-free  survival  showed  no 
significant difference between patients with and with-
out riPSA (Fig. 1). We analyzed the impact of riPSA in 
the risk group using Kaplan–Meier curves (Fig. 2). Log-
rank test revealed no significant association (P = 0.9095) 
between the presence of riPSA and the risk of biochemi-
cal failure in the high-risk group (Fig. 2A), but demon-
strated a significant association (P = 0.0354) between 
the presence of riPSA and the risk of biochemical failure 
in the low- and intermediate-risk group (Fig. 2B).
On univariate analysis (Table 2), among all of the 
clinical  and  dosimetric  parameters  analyzed,  only 
the number of HIFU sessions was significant (hazard 
ratio, 18.834; 95% confidence interval, 3.736–94.947, 
P = 0.000). riPSA remained of borderline relevance 
without statistical significance, exhibiting a tendency 
to be associated with a higher biochemical failure rate 
(hazard ratio, 4.239; 95% confidence interval, 0.967–
18.576,  P  =  0.055).  Multivariate  analysis  among 
paremeters,  including  Gleason  score,  riPSA,  PSA 
nadir, HIFU session numbers, showed that riPSA and 
the number of HIFU sessions were significant (hazard 
ratio, 4.955; 95% confidence interval, 1.023–23.997, 
P = 0.047; hazard ratio 22.460; 95% confidence inter-
val, 3.729–135.266; P = 0.001 for riPSA and number 
of HIFU sessions, respectively) (Table 2).
Table 1. Patients background characteristics.
ripsA+ ripsA- P value
neoadjuvant hormonal therapy* 0.000
  Yes 6.3 38.3
  no 46.3 9.1
Stage* 0.343
  T1c 16.6 10.7
  T2a 13 17.2
  T2b 13 10.7
  T2c 10.7 8.3
D’Amico risk group* 0.181
  Low 18.5 11.3
  Intermediate 17.3 13.1
  high 17.9 22
Age; median (min-max) 62 (52–86) 62 (54–82) 0.595
gS; median (min-max) 5 (5–10) 7 (4–10) 0.485
iPSA; median (min-max) 10.87 (2.20–26.91) 9.70 (3.8–45.69) 0.558
PSA nadir (ng/ml); median (min-max) 0.51 (0.01–3.31) 0.01 (0.00–2.77) 0.018
number of hIFU sessions* 0.993
  Once 47.7 42.6
  Twice 5.1 4.5
note: *Values are expressed as the percent of entities.
Abbreviations: riPSA, rapid increase in the serum PSA; gS, gleason score; iPSA, initial PSA.Inamoto et al
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levels are almost universally present for an extended 
period, showing great variability among patients and 
at different time points. Hence, for definition of suc-
cessful therapy, the expected course of the PSA level 
following treatment is a decline to a nadir.
It is generally thought that the PSA level decreases 
continuously  after  potentially  successful  radiation 
treatment for prostate cancer, and that an increase in 
the PSA level might reflect disease recurrence. How-
ever, prostate cancer patients often show a temporary 
rise in their PSA levels after radiation therapy. This is 
known as the "PSA bounce", which does not reflect 
disease recurrence.
In  the  present  study,  riPSA  was  defined  as  an 
increase $0.2 ng/ml with spontaneous return to the 
prebounce level or lower—the same definition as that 
used for the PSA bounce. The PSA bounce phenom-
enon was first recognized in patients receiving com-
bined external beam radiation therapy and permanent 
prostate  implants,  and  its  exact  cause  is  unclear, 
although suggestions have included radiation therapy-
induced prostatitis resulting from compromised mem-
brane integrity. Previous studies have also implicated 
recent instrumentation such as biopsy, bicycle riding, 
or recent ejaculation as causes. There are various def-
initions of the PSA bounce.1–3 Many have defined it as 
an increase in the PSA level by 0.1%,4 0.2%,5,6 or 15%7 
above the nadir. T stage, prostate volume, irradiation 
dose, hormonal therapy, and age have been reported 
as predictive factors for the PSA bounce.8 In a recent 
review, younger age was the only consistent predic-
tive factor.8 Most studies that have examined the PSA 
bounce have been based on patients who underwent 
radiation  therapy.  The  onset  of  PSA  bounce  after 
radiation  therapy  usually  occurs  during  mid-term 
through long-term follow-up. In patients undergoing 
permanent implant brachytherapy, the time of onset 
of the PSA bounce varies from 12 months–24 months 
depending on the definition.5,9 Although it is believed 
that the PSA bounce never occurs with HIFU,10 no 
researchers have yet focused on the PSA increase in 
the acute phase after HIFU therapy. In our present 
series, after each treatment, PSA showed a marked 
increase at 2 days, and accordingly we coined the 
term "rapid increase of the PSA level" to describe it. 
To our knowledge, this is the first published study 
to hav analyzed patients showing a rapid increase of 
the PSA level after HIFU therapy. Because HIFU is 
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Figure 1. Biochemical recurrence-free survival curve for all patients who 
underwent hIFU treatment. riPSA = rapid increase of the PSA level.
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Figure  2.  Biochemical  recurrence-free  survival  curve  for  the  patients 
who underwent hIFU treatment. riPSA = rapid increase of the PSA level. 
A) Biochemical recurrence-free survival curve for the D’Amico high-risk 
group. B) Biochemical recurrence-free survival curve for the D’Amico 
low- and intermediate-risk group.
Discussion
Reduction of the PSA level after curative treatment 
is a hallmark by which treatment success for pros-
tate cancer is defined. In the setting of radical pros-
tatectomy, stably undetectable PSA levels are usually 
achieved within a few weeks after surgery. This situ-
ation is different in the setting of prostate cancer that 
is treated using non-surgical methods including radi-
ation  therapy  and  HIFU,  because  measurable  PSA PSA increase after high-intensity focused ultrasound for localized prostate cancer
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non-ionizing, the cause of this PSA increse may dif-
fer from radiation therapy. It can be speculated that 
ultrasound-induced prostate tissue necrosis may be 
the  histological  basis  of  this  phenomenon. At  the 
point where the waves emitted from the HIFU unit 
are focused, the sudden and intense absorption of the 
ultrasound beam creates a sudden elevation of tem-
perature (to greater than 85 °C), which destroys the 
prostate cancer cells located in the target zone. The 
extremely high intensity of the ultrasound in prostate 
tissue may itself account for discrete tissue necrosis, a 
phenomenon that is likely absent after external beam 
radiation therapy, which in turn can also result in a 
steep increase of the PSA level. If this riPSA can be 
regarded as a form of bounce phenomenon, then the 
time until the bounce is much shorter than that result-
ing from radiation therapy. PSA kinetics after HIFU 
may follow a course different from that with other 
modalities, especially radiation therapy. Unlike radia-
tion, HIFU is an ablation technology, which rapidly 
increases  the  temperature,  resulting  in  coagulative 
necrosis; this means that PSA levels decline quickly 
after rapid increase of PSA in response to tissue necro-
sis and take only 3 through 6 months to reach a nadir. 
For radiation, the behaviour of PSA is more complex. 
The radiation does not of itself kill cells. Radiation 
therapy works by damaging the DNA of cells. Gener-
ally, this is repairable but sometimes it produces fatal 
damage so that the DNA damage is inherited through 
cell  division,  accumulating  damage  to  the  cancer 
cells, causing them to die or reproduce slowly. The 
cells with fatally damaged DNA still continue to pro-
duce PSA and this only ceases when they die. As a 
result, PSA declines quite slowly after radiotherapy, 
showing the marked contrast to HIFU.
Two precipitating factors—lack of hormonal ther-
apy and a higher PSA nadir—were found to increase 
the risk of riPSA (Table 2). Hormonal therapies have 
a repressive effect on follow-up PSA levels, as might 
be expected. In our series, 83.5% of patients with-
out hormonal therapy showed the riPSA, compared 
with 14.1% of patients who received hormonal ther-
apy. Although, neither hormonal therapy nor riPSA 
showed a significant tendency to be related to bio-
Table 2. Multivariate Cox regression analysis of BCrF survival.
Variable Univariate Multivariate
HR 95% cI P value HR 95% cI P value
neoadjuvant hormonal therapy
  no 1 –
  Yes 0.430 0.123 1.502 0.186
Stage
  T1c and T2a 1 –
  T2b and T2c 0.462 0.171 1.252 0.129
D’Amico
  Low-risk 1 –
  Intermediate-risk 1.738 0.659 4.582 0.264
Age –
(continuous variable) 0.985 0.920 1.055 0.675
gleason score
  Lesser than 7 1 1
  7 or greater 0.726 0.208 2.531 0.615 0.435 0.112 1.689 0.229
riPSA
  no 1 1
  Yes 4.239 0.967 18.576 0.055 4.955 1.023 23.997 0.047
iPSA
(continuous variable) 1.007 0.935 1.085 0.844 –
PSA nadir (ng/ml)
(continuous variable) 1.675 0.931 3.012 0.085 2.024 0.991 4.135 0.053
number of hIFU sessions
  Once 1 1
  Twice 18.834 3.736 94.947 0.000 22.460 3.729 135.266 0.001
Abbreviations: riPSA, rapid increase in the serum PSA; BCrF survival, biochemichal recurrence free survival; iPSA, initial PSA.publish with Libertas Academica and 
every scientist working in your field can 
read your article 
“I would like to say that this is the most author-friendly 
editing process I have experienced in over 150 
publications. Thank you most sincerely.”
“The communication between your staff and me has 
been terrific.  Whenever progress is made with the 
manuscript, I receive notice.  Quite honestly, I’ve 
never had such complete communication with a 
journal.”
“LA is different, and hopefully represents a kind of 
scientific publication machinery that removes the 
hurdles from free flow of scientific thought.”
Your paper will be:
•  Available to your entire community 
free of charge
•  Fairly and quickly peer reviewed
•  Yours!  You retain copyright
http://www.la-press.com
Inamoto et al
106  Clinical Medicine Insights: Oncology 2011:5
chemical  recurrence  on  univariate  analysis  (Table 
2), multivariate Cox regression analysis showed that 
riPSA and the number of HIFU sessions were predic-
tors of biochemical recurrence (Table 2). This provides 
evidence that riPSA may not automatically dictate 
hormonal therapy. In our series, log-rank test demon-
strated a significant association (P = 0.0354) between 
the presence of riPSA and the risk of biochemical 
failure only in the low- and intermediate-risk group 
(Fig. 2B). riPSA may thus be potentially predictive 
of biochemical recurrence in selected patient popu-
lations, especially those with non-high-risk cancer. 
In our cohort, prognostic value of riPSA was lost in 
high-risk cancer. This is explainable by the fact that 
the definition for high-risk group does not account for 
some adverse variables. High-risk prostate cancer is a 
quite heterogeneous group that includes patients with 
clinically locally advanced stage disease at diagno-
sis, in which some have micrometastatic disese, some 
have local extension, and some have neither. Hence, 
high-risk patients with a riPSA after irradiation may 
be  a  heterogeneous  group,  including  patients  with 
truly localized failure as well as those with metastatic 
disease. Further risk stratification within this hetero-
geneous high-risk group would be useful to assess 
which patients are most likely to fail HIFU therapy.
conclusions
We have found that patients with low- and intermedi-
ate-risk prostate cancer who demonstrate a post-HIFU 
riPSA have an increased risk of biochemical failure.
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